2-((1r,4r)-4-(4-(4-(benzo[d]oxazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)cyclohexyl)acetic acid | 1245708-85-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-((1r,4r)-4-(4-(4-(benzo[d]oxazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)cyclohexyl)acetic acid
• CAS: 1245708-85-3
• 化学式: C₂₉H₂₈N₂O₄
• 分子量: 468.552
• InChiKey: SIKGBQSGSOEPGB-MXVIHJGJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.77
• 重原子数：
  35.0
• 可旋转键数：
  5.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  75.8
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  2-氯苯并恶唑 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 lithium hydroxide monohydrate 、 sodium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 为溶剂， 反应 10.0h， 生成 2-((1r,4r)-4-(4-(4-(benzo[d]oxazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)cyclohexyl)acetic acid
  参考文献：
  名称：

  Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors

  摘要：

  Diacylglycerol acyltransferase 1 (DGAT1) presents itself as a potential therapeutic target for obesity and diabetes for its important role in triglyceride biosynthesis. Herein we report the rational design of a novel class of DGAT1 inhibitors featuring a benzomorpholine core (23n). SAR exploration yielded compounds with good potency and selectivity as well as reasonable physical and pharmacokinetic properties. This class of DGAT1 inhibitors was tested in rodent models to evaluate DGAT1 inhibition as a novel approach for the treatment of metabolic diseases. Compound 23n conferred weight loss and a reduction in liver triglycerides when dosed chronically in mice with diet-induced obesity and depleted serum triglycerides following a lipid challenge.

  DOI：

  10.1021/ml400527n

文献信息

• BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE
  申请人：Zhou Gang

  公开号：US20120022057A1

  公开（公告）日：2012-01-26

  The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below (I).

  本发明涉及一种新型杂环化合物，作为二酰基甘油酰基转移酶（“DGAT”）抑制剂，包括该杂环化合物的制药组合物，并且该化合物可用于治疗或预防心血管疾病、代谢紊乱、肥胖或肥胖相关疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损。本发明的一种示例化合物如下所示（I）。
• Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors
  作者：Gang Zhou、Nicolas Zorn、Pauline Ting、Robert Aslanian、Mingxiang Lin、John Cook、Jean Lachowicz、Albert Lin、Michelle Smith、Joyce Hwa、Margaret van Heek、Scott Walker

  DOI：10.1021/ml400527n

  日期：2014.5.8

  Diacylglycerol acyltransferase 1 (DGAT1) presents itself as a potential therapeutic target for obesity and diabetes for its important role in triglyceride biosynthesis. Herein we report the rational design of a novel class of DGAT1 inhibitors featuring a benzomorpholine core (23n). SAR exploration yielded compounds with good potency and selectivity as well as reasonable physical and pharmacokinetic properties. This class of DGAT1 inhibitors was tested in rodent models to evaluate DGAT1 inhibition as a novel approach for the treatment of metabolic diseases. Compound 23n conferred weight loss and a reduction in liver triglycerides when dosed chronically in mice with diet-induced obesity and depleted serum triglycerides following a lipid challenge.